Champions Oncology(US:CSBR)2025-12-15 21:59Revenue Performance - Oncology revenue for the three months ended October 31, 2025, was $15.0 million, an increase of 11.5% from $13.5 million in the same period of 2024 [104]. - For the six months ended October 31, 2025, oncology revenue totaled $29.0 million, reflecting a 5.4% increase from $27.6 million in the prior year [104]. Expenses - Research and development expenses for the three months ended October 31, 2025, increased by approximately $927,000 or 54.9% to $2.6 million compared to $1.7 million in 2024 [111]. - Total costs and operating expenses for the three months ended October 31, 2025, were $14.9 million, a 16.4% increase from $12.8 million in the prior year [103]. - Sales and marketing expenses for the three months ended October 31, 2025, were $2.0 million, an increase of 14.1% from $1.8 million in the same period of 2024 [115]. - General and administrative expenses for the three months ended October 31, 2025, increased by $1.1 million, or 57.4%, to $3.0 million compared to $1.9 million in the same period of 2024 [116]. Net Income and Cash Flow - The company reported a net loss of $230,000 for the six months ended October 31, 2025, compared to a net income of $2.0 million for the same period in 2024 [101]. - For the six months ended October 31, 2025, net cash used in operating activities was $1.1 million, a significant decrease from net cash provided of $28,000 in the same period of 2024 [117]. - Net cash used in investing activities for the six months ended October 31, 2025, was approximately $288,000, compared to $94,000 in the same period of 2024 [118]. - Net cash provided by financing activities was $154,000 for the six months ended October 31, 2025, down from $202,000 in the same period of 2024 [119]. Financial Position - As of October 31, 2025, the company had an accumulated deficit of approximately $80.1 million and cash of $8.5 million [101]. - The company has no off-balance sheet debt or similar obligations [121]. - The company is classified as a smaller reporting company and is not required to provide additional market risk disclosures [122]. Strategic Outlook - The cost of oncology revenue for the three months ended October 31, 2025, decreased by $166,000 or 2.2% to $7.3 million compared to $7.4 million in the prior year [110]. - The company anticipates improvements in the overall cost structure as radiolabeling work transitions into its labs, which may reduce the cost of oncology revenue [110]. - The company is exploring strategic options to create additional value from its drug discovery business, including potential spin-out transactions or capital raises [100]. Accounting Policies - There have been no changes to critical accounting policies during the six months ended October 31, 2025 [120].